Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023)
Denali Therapeutics' (DNLI) quarterly EBIT Margin came in at 8981.45% in Q3 2023, down 579668.0% year-on-year from N/an in Q3 2022, and down 15595.1% on a QoQ basis from 57.96% in Q2 2023.
Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of EBIT Margin data on file, last reported at 8981.45% in Q3 2023.
- On a quarterly basis, EBIT Margin fell 579668.0% year-over-year to 8981.45% in Q3 2023; TTM through Jun 2024 was 37938.04%, a 3789042.0% decrease from a year earlier, with the FY2023 full-year figure at 59.51%, up 26481.0% from the prior year.
- EBIT Margin for Q3 2023 stood at 8981.45%, down from 57.96% in the prior quarter.
- Over the last five years, EBIT Margin for DNLI reached as high as 77.04% in Q4 2020 and fell as low as 115321.15% in Q1 2020.
- Historically, EBIT Margin has averaged 7301.99% across 5 years, with a median of 1010.89% in 2019.
- Across the five-year window, EBIT Margin slumped 11431026 bps in 2020 and soared 11442214 bps in 2021, its largest moves.
- Year by year, EBIT Margin stood at 1236.26% in 2019, then surged by 106 bps to 77.04% in 2020, then plunged by 306 bps to 158.51% in 2021, then tumbled by 565 bps to 1053.44% in 2022, then tumbled by 753 bps to 8981.45% in 2023.
- Per Business Quant data, the three most recent EBIT Margin figures were 8981.45% in Q3 2023, 57.96% in Q2 2023, and 343.8% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -8,981.45% |
| Jun 30, 2023 | 57.96% |
| Mar 31, 2023 | -343.80% |
| Dec 31, 2022 | -1,053.44% |
| Sep 30, 2022 | -3,184.77% |
| Jun 30, 2022 | -117.03% |
| Mar 31, 2022 | -157.80% |
| Dec 31, 2021 | -158.51% |
| Sep 30, 2021 | -1,619.55% |
| Jun 30, 2021 | -412.11% |
| Mar 31, 2021 | -899.02% |
| Dec 31, 2020 | 77.04% |
| Sep 30, 2020 | -640.35% |
| Jun 30, 2020 | -1,054.50% |
| Mar 31, 2020 | -115,321.15% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -1,150.62% |
| Jun 30, 2019 | -1,531.55% |
| Mar 31, 2019 | -1,010.89% |
| Dec 31, 2018 | 59.46% |